Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Lisata Therapeutics (LSTA) Cost of Revenue (2016 - 2017)

Lisata Therapeutics filings provide 8 years of Cost of Revenue readings, the most recent being $8.0 million for Q1 2017.

  • For the quarter ending Q1 2017, Cost of Revenue rose 29.13% year-over-year to $8.0 million, compared with a TTM value of $33.0 million through Mar 2017, up 43.15%, and an annual FY2016 reading of $31.1 million, up 54.45% over the prior year.
  • Cost of Revenue hit $8.0 million in Q1 2017 for Lisata Therapeutics, down from $9.2 million in the prior quarter.
  • The five-year high for Cost of Revenue was $9.2 million in Q4 2016, with the low at $2.4 million in Q1 2013.
  • Median Cost of Revenue over the past 5 years was $4.2 million (2013), compared with a mean of $5.2 million.
  • The sharpest move saw Cost of Revenue fell 20.59% in 2013, then surged 84.89% in 2016.
  • Year by year, Cost of Revenue stood at $3.3 million in 2013, then grew by 24.49% to $4.2 million in 2014, then soared by 48.51% to $6.2 million in 2015, then soared by 49.53% to $9.2 million in 2016, then dropped by 13.01% to $8.0 million in 2017.
  • According to Business Quant data, Cost of Revenue over the past three periods came in at $8.0 million, $9.2 million, and $8.6 million for Q1 2017, Q4 2016, and Q3 2016 respectively.